



Epidiolex[®] (cannabidiol) – DEA Descheduling

- On April 6, 2020, [GW Pharmaceuticals](#) announced that it received notification from the Drug Enforcement Administration (DEA) confirming that [Epidiolex \(cannabidiol\)](#) is no longer subject to the Controlled Substances Act (CSA).
 - This change takes effect immediately.
 - Following FDA approval, Epidiolex was initially placed in Schedule V of the CSA.
 - Following receipt of this DEA notification, GW has filed a post-approval supplement with the FDA to remove Schedule V designation from Epidiolex.
- Epidiolex is approved for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
- GW Pharmaceuticals will now begin the process of implementing these changes at the state level and through the Epidiolex distribution network.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.